<DOC>
	<DOCNO>NCT01652716</DOCNO>
	<brief_summary>To compare effect glycemic control ( HbA1c ) exenatide suspension administer weekly achieve exenatide administer twice daily 28 week subject type 2 diabetes mellitus . To examine long-term ( 52 week treatment ) safety effect glucose control exenatide suspension administer weekly subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>Efficacy Safety Exenatide Once Weekly Suspension Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>At least 18 year old Diagnosed type 2 diabetes mellitus HbA1c 7.1 11 % , inclusive , screen Fasting plasma glucose &lt; 280 mg/dL ( 15.5 mmol/L ) Body mass index ( BMI ) &lt; =45 kg/m2 , inclusive , screen Treated diet exercise stable regimen metformin , sulfonylurea , pioglitazone 2 agent History pancreatitis triglyceride &gt; =500 mg/dL Medullary carcinoma multiple endocrine neoplasia ( MEN2 ) family history either Active cardiovascular disease Presence congestive heart failure Liver disease History severe gastrointestinal disease Repeated severe hypoglycemia within last 6 month Any previous use exenatide glucagonlike peptide1 ( GLP1 ) analog Dipeptidyl peptidase4 ( DPP4 ) inhibitor use last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>